Drug profile · INN
zaleplon
SONATA
zaleplon (SONATA) is a gaba a receptor alpha-1/beta-1/gamma-2 positive allosteric modulator. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — zaleplon
- US status
- approved
- Class
- Nervous system (N05)
- Route
- ORAL
- Patents
- 2
- Programs
- 1
- Data quality
- 0.89
Quick answer
zaleplon (SONATA) is a gaba a receptor alpha-1/beta-1/gamma-2 positive allosteric modulator. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator
Primary target: GABA A receptor alpha-1/beta-1/gamma-2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 7348429
Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide(zaleplon) and crystalline forms of zaleplon accessible with the process
granted -
US 6884888
Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon)
expired
Frequently asked questions
What is zaleplon?
zaleplon (SONATA) is a gaba a receptor alpha-1/beta-1/gamma-2 positive allosteric modulator. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for zaleplon?
SONATA is a marketed brand name for zaleplon. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of zaleplon?
zaleplon has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.